Tag: antiretroviral therapy (art)

COVID-19 Causes Major Interruption in Global HIV Progress

From testing to treatment, Global Fund HIV services have been hampered by COVID-19. “We’ve been set back by COVID but we’ve seen remarkable resilience, a...

CAB/RPV LA Not for Everyone

“One of the most important considerations before switching HIV patients to injectable long-acting cabotegravir/rilpivirine [CAB/RPV LA; Cabenuva, ViiV Healthcare] is for the patient and the...

HIV Acquisition on PrEP Rare, With Some Drug Resistance

Out of an estimated 104,000 people offered HIV preexposure prophylaxis (PrEP) to protect themselves from HIV, just 14 people acquired a strain of HIV resistant...

Liver Cancer Monotherapy Indication for Nivolumab Withdrawn

The indication for nivolumab (Opdivo) as monotherapy for hepatocellular carcinoma (HCC) for patients previously treated with sorafenib has been voluntarily withdrawn by the manufacturer, Bristol-Myers...

Failed viral suppression in CAB/RPV linked to 3 Risk Factors

A body mass index (BMI) ≥30 kg/m2, rilpivirine resistance–associated mutations, and the HIV-1 subtype A6/A1 can raise a person’s risk for confirmed virologic failure (CVF)...

Younger Adults With HIV Have Higher CVD Risk but Low ASCVD Scores

People age 40 and younger living with HIV have a higher risk for heart disease than even their over-40 peers living with HIV — and...

Dolutegravir Confirmed as Effective Second-Line HIV Therapy

Dolutegravir and ritonavir-boosted darunavir are equally effective second-line treatments for HIV-1, even for patients with resistance to nucleoside reverse-transcriptase inhibitors (NRTIs) in the regimen, a...

Lenacapavir Shows Viral Suppression in Drug-Resistant HIV

Dr Jean-Michel Molina The long-acting drug lenacapavir, a first-in-class capsid inhibitor, shows sustained viral suppression in a small cohort of heavily treatment-experienced patients with multidrug-resistant...

Is HIV Criminalization the No. 1 Barrier to Ending the Epidemic?

For many people, being told that they are HIV positive is no longer a death sentence. But for Robert Suttle, a Black gay man and...

Treatment Paradigm for Chronic HBV in Flux

These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD,...

Pediatric TB – More Work Needed, Especially With HIV Coinfection

Despite recent advances in the diagnosis, treatment, and prevention of pediatric tuberculosis in children living with HIV (CLHIV) and HIV-exposed uninfected children (HEU), several unmet...

The Changing Brain Signature of HIV

Combination antiretroviral therapy (cART) has shifted HIV infection from a fatal to a chronic condition. New evidence now suggests this has been accompanied by a...

HIV PrEP Prescriptions Often Go Unfilled

Same-day HIV pre-exposure prophylaxis (PrEP) prescriptions and insurance navigation services led 70% of people at a Detroit sexually transmitted infection clinic to ask for a...

Aging With HIV Adds to Comorbidity Burden

The age of antiretroviral therapy (ART) for HIV is in its third decade, and many of the patients who live in areas of the world...

HIV PrEP Referrals Lag for Black MSM, Trans Adults

State health departments were most likely to refer heterosexual adults for HIV preexposure prophylaxis (PrEP) appointments and least likely to refer transgender and Black adults,...

Starting ART Before MD Visit Speeds Care

Time to enrollment in HIV treatment dropped by 53% when clinicians sent people new to HIV treatment home from intake with a bottle of universal...

Switch to Integrase Inhibitor Regimen Safe and Effective

Switching patients with HIV from a protease inhibitor–based antiretroviral therapy regimen to an integrase inhibitor–based regimen can be performed safely, with maintenance of high levels...

Once-Weekly Investigational MK-8507 Potent Even at Low Doses

A single dose of MK-8507, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), reduced HIV-1 viral loads for at least 1 week with efficacy comparable to...

Weight Gain Persists as HIV-Treatment Issue

People living with HIV who put on extra pounds and develop metabolic syndrome or related disorders linked in part to certain antiretroviral agents remain a...

Brazilian Patient in HIV Remission, Negative Antibody Test

A 35-year-old Brazilian man who participated in a trial in which he received an intensified antiretroviral regimen plus supplemental vitamin B₃ for 48 weeks has joined...